FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3038833360> ?p ?o ?g. }

• W3038833360 endingPage "1439" @default.
• W3038833360 startingPage "1429" @default.
• W3038833360 abstract "Background: Conservative management with progestin is a treatment option for atypical hyperplasia (AH). However, pathologic diagnosis of residual/recurrent lesions is often problematic because of the profound morphologic changes induced by progestin and the lack of established diagnostic criteria for progestin-treated residual AH. Methods: We conducted a longitudinal study of 265 endometrial biopsies from 54 patients with a history of AH on progestin therapy. Patient outcomes were divided into 3 categories after morphologic review and immunohistochemical staining with phosphatase and tensin homolog (PTEN) and paired box 2 (PAX2): (1) persistent or residual disease; (2) recurrent disease; (3) complete response. All specimens were classified into 3 categories based on morphology: (1) persistent/recurrent disease (nonresponse), (2) morphologically uncertain response, (3) optimally treated (complete response). The staining patterns of PTEN/PAX2 were tracked over time in individual patients and correlated with morphologic findings before and after progestin therapy. Results: Our data showed that aberrant expression patterns of PTEN and/or PAX2 were identified in 48 (88.9%) of the 54 primary biopsies and persisted in persistent/recurrent AH across serial endometrial biopsies (n=99, P <0.00001), while normal PTEN and PAX2 expressions were consistently observed in optimally treated cases (n=84, P <0.00001). More importantly, follow-up biopsies that showed a morphologically uncertain response but a PTEN/PAX2 expression pattern identical to the initial biopsy were significantly correlated with persistent or recurrent disease (n=18, P =0.000182), as evidenced by areas with morphologic features diagnostic of AH on subsequent biopsy. Conclusions: Biomarker PTEN/PAX2 signatures offer a valuable diagnostic aid to identify residual AH in progestin-treated endometrial samples for which the biomarker status from preprogestin treated AH is known. The findings of this study are promising for a possible future change of diagnostic practice." @default.
• W3038833360 created "2020-07-10" @default.
• W3038833360 creator A5012807831 @default.
• W3038833360 creator A5022499603 @default.
• W3038833360 creator A5029456681 @default.
• W3038833360 creator A5035541971 @default.
• W3038833360 creator A5036645530 @default.
• W3038833360 creator A5041323170 @default.
• W3038833360 creator A5043805914 @default.
• W3038833360 creator A5064306401 @default.
• W3038833360 creator A5065045811 @default.
• W3038833360 creator A5086654870 @default.
• W3038833360 date "2020-07-03" @default.
• W3038833360 modified "2023-10-15" @default.
• W3038833360 title "Specific Biomarker Expression Patterns in the Diagnosis of Residual and Recurrent Endometrial Precancers After Progestin Treatment" @default.
• W3038833360 cites W1968268802 @default.
• W3038833360 cites W1979652171 @default.
• W3038833360 cites W1992757917 @default.
• W3038833360 cites W1995293237 @default.
• W3038833360 cites W1999150241 @default.
• W3038833360 cites W2000516822 @default.
• W3038833360 cites W2005747556 @default.
• W3038833360 cites W2011974052 @default.
• W3038833360 cites W2012908122 @default.
• W3038833360 cites W2014989389 @default.
• W3038833360 cites W2024334890 @default.
• W3038833360 cites W2030442521 @default.
• W3038833360 cites W2041440766 @default.
• W3038833360 cites W2043933121 @default.
• W3038833360 cites W2046103294 @default.
• W3038833360 cites W2047111383 @default.
• W3038833360 cites W2062807253 @default.
• W3038833360 cites W2071624276 @default.
• W3038833360 cites W2081360823 @default.
• W3038833360 cites W2082798586 @default.
• W3038833360 cites W2095881173 @default.
• W3038833360 cites W2102353246 @default.
• W3038833360 cites W2148651857 @default.
• W3038833360 cites W2149884503 @default.
• W3038833360 cites W2167264978 @default.
• W3038833360 cites W2185449028 @default.
• W3038833360 cites W2188776694 @default.
• W3038833360 cites W2329537625 @default.
• W3038833360 cites W4234114680 @default.
• W3038833360 cites W4250290055 @default.
• W3038833360 doi "https://doi.org/10.1097/pas.0000000000001537" @default.
• W3038833360 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32931681" @default.
• W3038833360 hasPublicationYear "2020" @default.
• W3038833360 type Work @default.
• W3038833360 sameAs 3038833360 @default.
• W3038833360 citedByCount "11" @default.
• W3038833360 countsByYear W30388333602021 @default.
• W3038833360 countsByYear W30388333602022 @default.
• W3038833360 countsByYear W30388333602023 @default.
• W3038833360 crossrefType "journal-article" @default.
• W3038833360 hasAuthorship W3038833360A5012807831 @default.
• W3038833360 hasAuthorship W3038833360A5022499603 @default.
• W3038833360 hasAuthorship W3038833360A5029456681 @default.
• W3038833360 hasAuthorship W3038833360A5035541971 @default.
• W3038833360 hasAuthorship W3038833360A5036645530 @default.
• W3038833360 hasAuthorship W3038833360A5041323170 @default.
• W3038833360 hasAuthorship W3038833360A5043805914 @default.
• W3038833360 hasAuthorship W3038833360A5064306401 @default.
• W3038833360 hasAuthorship W3038833360A5065045811 @default.
• W3038833360 hasAuthorship W3038833360A5086654870 @default.
• W3038833360 hasConcept C126322002 @default.
• W3038833360 hasConcept C142724271 @default.
• W3038833360 hasConcept C143998085 @default.
• W3038833360 hasConcept C190283241 @default.
• W3038833360 hasConcept C204232928 @default.
• W3038833360 hasConcept C2775934546 @default.
• W3038833360 hasConcept C2776607906 @default.
• W3038833360 hasConcept C2777164284 @default.
• W3038833360 hasConcept C2777609662 @default.
• W3038833360 hasConcept C2779549131 @default.
• W3038833360 hasConcept C2781197716 @default.
• W3038833360 hasConcept C55493867 @default.
• W3038833360 hasConcept C71924100 @default.
• W3038833360 hasConcept C86554907 @default.
• W3038833360 hasConcept C86803240 @default.
• W3038833360 hasConceptScore W3038833360C126322002 @default.
• W3038833360 hasConceptScore W3038833360C142724271 @default.
• W3038833360 hasConceptScore W3038833360C143998085 @default.
• W3038833360 hasConceptScore W3038833360C190283241 @default.
• W3038833360 hasConceptScore W3038833360C204232928 @default.
• W3038833360 hasConceptScore W3038833360C2775934546 @default.
• W3038833360 hasConceptScore W3038833360C2776607906 @default.
• W3038833360 hasConceptScore W3038833360C2777164284 @default.
• W3038833360 hasConceptScore W3038833360C2777609662 @default.
• W3038833360 hasConceptScore W3038833360C2779549131 @default.
• W3038833360 hasConceptScore W3038833360C2781197716 @default.
• W3038833360 hasConceptScore W3038833360C55493867 @default.
• W3038833360 hasConceptScore W3038833360C71924100 @default.
• W3038833360 hasConceptScore W3038833360C86554907 @default.
• W3038833360 hasConceptScore W3038833360C86803240 @default.
• W3038833360 hasIssue "10" @default.
• W3038833360 hasLocation W30388333601 @default.
• W3038833360 hasOpenAccess W3038833360 @default.

• next